EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 715 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR To My Fellow Nurses May 13, 2021 Durvalumab Modestly Improves Survival in Advanced Biliary Tract Cancer February 10, 2022 Amid Coronavirus Outbreak and Panic Buying, Stores Introduce Special Shopping Times... March 18, 2020 ESMO Calls for Cancer to Remain a Flagship Priority in the... November 5, 2025 Load more HOT NEWS Increase in Node-Positive and Stage III Breast Cancer After Two Months... 12 myths about sun safety debunked Remote Monitoring of Patients Treated with Oral Anticancer Drugs Improves Patient... Moving target – retrotransposable elements and cancer
